Author

A. Pankow

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Organism:rat· 1

Frequent Co-Authors

B. Murrell· 4 shared C. Kim· 3 shared D. J. Sheward· 3 shared E. Urgard· 3 shared G. M. McInerney· 3 shared J. M. Coquet· 3 shared L. Hanke· 3 shared L. Perez Vidakovics· 3 shared

Activity by Year

2021-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

B. Murrell

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)

D. J. Sheward, C. Kim, R. A. Ehling, A. Pankow, X. Castro Dopico, D. P. Martin, S. T. Reddy, J. Dillner, G. B. Karlsson Hedestam, J. Albert, B. Murrell

This study assesses neutralizing antibody responses against the SARS-CoV-2 Omicron variant, showing reduced potency compared to the pandemic founder but with some cross-neutralizing capacity in vaccinated individuals.

bioRxiv · Dec 19, 2021 · PreprintImmunology

Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralising SARS-CoV-2 nanobodies

L. Hanke, D. J. Sheward, A. Pankow, L. Perez Vidakovics, V. Karl, C. Kim, E. Urgard, N. L. Smith, J. Astorga-Wells, S. Ekström, J. M. Coquet, G. M. McInerney, B. Murrell

This study identifies potent cross-neutralizing SARS-CoV-2 nanobodies from an alpaca immune repertoire using phage display and epitope mapping.

bioRxiv · Jul 25, 2021Immunology

Driving potent neutralization of a SARS-CoV-2 Variant of Concern with a heterotypic boost

D. J. Sheward, M. Mandolesi, E. Urgard, C. Kim, L. Hanke, L. Perez Vidakovics, A. Pankow, N. L. Smith, X. Castro Dopico, G. M. McInerney, J. M. Coquet, G. Karlsson Hedestam, B. Murrell

A single dose of a VOC-derived RBD protein boost enhances potent neutralizing antibodies against both Wu-Hu-1 and the VOC in previously vaccinated rhesus macaques.

bioRxiv · Apr 3, 2021 · PreprintImmunology

A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo

L. Hanke, H. Das, D. Sheward, L. Perez Vidakovics, E. Urgard, A. Moliner Morro, K. Changil, V. Karl, A. Pankow, N. Smith, B. Porebski, O. Fernandez-Capetillo, E. Sezgin, G. Pedersen, J. M. Coquet, , G. M. McInerney

A bispecific nanobody neutralizes SARS-CoV-2 and its variant B.1.351 by inducing spike trimer-dimers that prevent ACE2 binding.

bioRxiv · Mar 20, 2021Immunology